المؤلفون: Bischoff, H., Bigot, C., Moinard, F., Pflumio, C., Fischbach, C., Kalish Weindling, M., Alt, M., Pierard, L., Petit, T., Demarchi, M.F., Kurtz, J.E., Karouby, D., Coliat, P., Cox, D., Pivot, X., Bender, L., Trensz, P.

المصدر: Annals of Oncology ; volume 32, page S504 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.602Test
https://api.elsevier.com/content/article/PII:S0923753421028313?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421028313?httpAccept=text/plainTest

المؤلفون: Bischoff, H., Bigot, C., Moinard-Butot, F., Pflumio, C., Fischbach, C., Kalish, M., Kurtz, J. E., Pierard, L., Demarchi, M., Karouby, D., Coliat, P., Pivot, X., Petit, T., Cox, D. G., Goepp, L., Bender, L., Trensz, P.

المصدر: Breast Cancer Research & Treatment; 2/15/2023, Vol. 198 Issue 1, p23-29, 7p

مستخلص: Purpose: A 4-weekly schedule of pegylated liposomal doxorubicin (PLD) has been approved for the treatment of metastatic breast cancer (MBC). Phase II trials have suggested interest in a 2-weekly regimen. This study aimed to compare the efficacy and safety of these two schedules. Methods: Data from MBC patients treated with PLD between 2011 and 2021 were retrospectively collected. The objective was to demonstrate the noninferiority of the 2-weekly versus the 4-weekly schedule in terms of 6-month progression-free survival (PFS). The prespecified noninferiority margin was calculated as 1.20. A propensity score to receive either schedule was estimated using a gradient boosting algorithm. Survival analyses using Cox regression models weighted by the propensity score were performed to compare the schedules. Results: Among the 192 patients included, 96 (50%) underwent each schedule. The median number of previous systemic therapies was 4 (IQR, 3 to 6). Anthracyclines were previously given in early breast cancer in 63.9% of patients. The median follow-up was 10.0 months (IQR, 5.0 to 20.1). A comparable distribution of adverse events was observed. The median PFS was 3.2 months (95% CI, 2.9 to 3.9), and the median overall survival was 12.1 months (95% CI, 10.8 to 14.9). The weighted hazard ratio for PFS was 1.12 (90% CI, 0.82 to 1.54), including the noninferiority boundaries. Conclusion: PLD appeared to be a well-tolerated drug in this heavily pretreated MBC population. The efficacy and safety of the 2-weekly schedule did not provide any advantage, suggesting no interest in changing the registered regimen. [ABSTRACT FROM AUTHOR]

: Copyright of Breast Cancer Research & Treatment is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Bischoff, H., Bigot, C., Moinard-Butot, F., Pflumio, C., Fischbach, C., Kalish, M., Kurtz, J. E., Pierard, L., Demarchi, M., Karouby, D., Coliat, P., Pivot, X., Petit, T., Cox, D. G., Goepp, L., Bender, L., Trensz, P.

المصدر: Breast Cancer Research and Treatment ; volume 198, issue 1, page 23-29 ; ISSN 0167-6806 1573-7217

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1007/s10549-022-06844-5Test

المؤلفون: Karouby, D, Vallet, C, Bocquet, F, Paubel, P

مصطلحات موضوعية: Drug supply/logistics (including: computer-aided drug dispatching and ward pharmacies)

الوصف: Background The patent expiries of leading biological products and the development of biosimilars create opportunities for cost savings. No studies have been carried out in the French hospital market. Purpose To perform a cost saving modelling analysis and investigate the potential factors that could affect the price of drugs. Materials and Methods We carried out a comparative study in French healthcare facilities, representing about 65% of national hospital beds, of the price of erythropoietic factors. The data were collected on procurement procedures operative as of 1 January 2012. Results 25 care facilities agreed to participate in the study. The overall sales turnover reached €15 M. Biosimilars represent less than 1% market share. All the establishments granted a discount of between 5% and 69% on the prices fixed by negotiation between the Comité Economique des Produits de Santé and the manufacturers, depending on the category (drugs, biosimilars or original biopharmaceuticals). The average discounts ranged from 11% to 73%. Binocrit, the main biosimilar represented was 25.6% less expensive than its original medicine Eprex. Based on French hospital financing, we show a 24.7% cost saving if a high interchangeability rate is adopted. Some participants could save up to 50% of their budget. We identified and analysed three criteria known to have a far-reaching effect on the drugs price. We observe no or little effect of the type of procurement procedure and specified quantity of medicine. The starting date of the contract is the primary criterion when purchasing drugs. The impact of these criteria varied depending on the drug in question and no general conclusions about medicines could be drawn. Conclusions The market for biosimilars is growing at a faster rate than the global prescription-drug market. Many top-selling biologicals are due to lose patent protection over the next few years. The great potential for cost savings apparent in our study could be investigated in other countries. No conflict of interest.

وصف الملف: text/html

العلاقة: http://ejhp.bmj.com/cgi/content/short/20/Suppl_1/A89-aTest; http://dx.doi.org/10.1136/ejhpharm-2013-000276.248Test

الإتاحة: https://doi.org/10.1136/ejhpharm-2013-000276.248Test
http://ejhp.bmj.com/cgi/content/short/20/Suppl_1/A89-aTest

المؤلفون: Besson, C., Karouby, D., Gass-Jegu, F., Martel, C., El Aatmani, A., Herbrecht, R., Gourieux, B.

المصدر: Le Pharmacien Hospitalier et Clinicien ; volume 49, issue 3, page 241 ; ISSN 2211-1042

مصطلحات موضوعية: Pharmacology (medical)

الإتاحة: https://doi.org/10.1016/j.phclin.2014.04.069Test
https://api.elsevier.com/content/article/PII:S2211104214001143?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2211104214001143?httpAccept=text/plainTest

المؤلفون: Dubret, L., Karouby, D., Zupan, V., Foucher, S., Rieutord, A., Roy, S.

المصدر: Le Pharmacien Hospitalier et Clinicien ; volume 47, page S67 ; ISSN 2211-1042

مصطلحات موضوعية: Pharmacology (medical)

الإتاحة: https://doi.org/10.1016/j.phclin.2011.12.162Test
https://api.elsevier.com/content/article/PII:S2211104211003602?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2211104211003602?httpAccept=text/plainTest

المؤلفون: Karouby, D., Bocquet, F., Chevalier, D., Paubel, P.

المصدر: Value in Health. (7):A400

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::0ed18cf2c222d9eed3299e0610e40470Test

المؤلفون: Karouby, D.¹, Bocquet, F.², Chevalier, D.³, Paubel, P.⁴

المصدر: Value in Health. Nov2013, Vol. 16 Issue 7, pA400-A400. 1p.